RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
30 août 2023 16h05 HE
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
11 août 2023 08h00 HE
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
07 juin 2023 08h00 HE
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
25 mai 2023 17h00 HE
|
RAPT Therapeutics, Inc.
-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to...
RAPT Therapeutics Reports First Quarter 2023 Financial Results
11 mai 2023 08h00 HE
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
03 mai 2023 08h00 HE
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
26 avr. 2023 16h19 HE
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
29 mars 2023 08h00 HE
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
14 mars 2023 08h00 HE
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and...
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
07 févr. 2023 08h00 HE
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...